Johnson & Johnson (NYSE: JNJ) is launching the latest version of its intravascular lithotripsy catheter for cracking calcium within the coronary arteries, which the company said it designed to cut treatment times in half. The Shockwave C2 Aero Fly catheter delivers ultrasonic energy at double the speed of its previous version and with less … [Read more...] about J&J launches faster Shockwave coronary catheter in the US
Johnson & Johnson
J&J delivers Shockwave data sustaining below-the-knee gains for two years
Johnson & Johnson MedTech (NYSE: JNJ) shared extended clinical findings from its Shockwave intravascular lithotripsy system, from a study aimed at clearing calcified vessel blockages below the knee in patients with peripheral artery disease. In late-breaking data presented at the Vascular InterVentional Advances 2026 conference in Las Vegas, … [Read more...] about J&J delivers Shockwave data sustaining below-the-knee gains for two years
Johnson & Johnson wins FDA approval for ThermoCool SmartTouch dual-energy ablation system
Johnson & Johnson (NYSE:JNJ) announced today that it received FDA approval for its dual-energy ThermoCool SmartTouch SF platform (DE STSF). The ThermoCool SmartTouch platform combines the ThermoCool SmartTouch SF catheter with the TruPulse generator. Combining the irrigated contact-force-sensing catheter with TruPulse enables the delivery of … [Read more...] about Johnson & Johnson wins FDA approval for ThermoCool SmartTouch dual-energy ablation system
Johnson & Johnson begins carotid IVL study enrollment
Johnson & Johnson (NYSE:JNJ) today announced the initiation of its SKYWARD clinical program for a new Shockwave IVL system. The SKYWARD FDA investigational device exemption (IDE) study evaluates the novel SkyRunner carotid intravascular lithotripsy (IVL) system for the treatment of calcified carotid arteries prior to stenting. SkyRunner, … [Read more...] about Johnson & Johnson begins carotid IVL study enrollment
Johnson & Johnson launches ThermoCool SmartTouch ablation tech in Europe
Johnson & Johnson (NYSE:JNJ) announced today that it launched its dual-energy ThermoCool SmartTouch platform in Europe. The launch expands access in the region to dual-energy catheter ablation for personalized care across workflows, anatomies and procedural strategies. J&J's ThermoCool SmartTouch platform combines the ThermoCool … [Read more...] about Johnson & Johnson launches ThermoCool SmartTouch ablation tech in Europe
Johnson & Johnson CMO explains advances behind ‘game-changer’ Shockwave C2 Aero catheter
With its $13 billion acquisition of Shockwave Medical in 2024, Johnson & Johnson added the market leader in intravascular lithotripsy (IVL) to its portfolio. Since then, the company has continued to build on that leadership position with new product rollouts. That includes the recent launch of Shockwave C2 Aero, the latest catheter system … [Read more...] about Johnson & Johnson CMO explains advances behind ‘game-changer’ Shockwave C2 Aero catheter
Johnson & Johnson launches next-gen Shockwave IVL catheter
Johnson & Johnson (NYSE:JNJ) today announced the global launch of the Shockwave C2 Aero coronary intravascular lithotripsy (IVL) catheter. The next-generation catheter leverages Shockwave IVL's unique mechanism of action and the safety and effectiveness profile of its legacy catheters. It features improved deliverability, enhanced lesion … [Read more...] about Johnson & Johnson launches next-gen Shockwave IVL catheter
Johnson & Johnson to acquire AtraVerse Medical and its transseptal access system
Johnson & Johnson (NYSE:JNJ) announced today that it entered into a definitive agreement to acquire Atraverse Medical. Atraverse develops the Hotwire transseptal access system, a novel radiofrequency guidewire left-heart access device. It enables zero-exchange left-heart access while acting as a rail for catheter-based therapy systems. … [Read more...] about Johnson & Johnson to acquire AtraVerse Medical and its transseptal access system
Johnson & Johnson launches head-to-head PFA trial pitting Varipulse against Boston Scientific’s Farapulse
Johnson & Johnson (NYSE:JNJ) today announced the initiation of a new trial evaluating competitive pulsed field ablation (PFA) technologies. The PERSIGMA RCT pits the company's Varipulse Pro PFA platform against the Boston Scientific Farapulse system. It compares the two leading PFA therapies in treating persistent AFib. Varipulse Pro, which … [Read more...] about Johnson & Johnson launches head-to-head PFA trial pitting Varipulse against Boston Scientific’s Farapulse
Johnson & Johnson reports positive Varipulse results at EHRA 2026
Johnson & Johnson today announced positive 12-month interim effectiveness and safety results from a study of its Varipulse system. Varipulse, the medtech giant's pulsed field ablation (PFA) platform, is designed to streamline ablation and mapping through a single integrated workflow with the Carto 3 mapping system. Carto 3 offers 3D heart … [Read more...] about Johnson & Johnson reports positive Varipulse results at EHRA 2026
